All News

As a caregiver, it is crucial that you learn to ask for help.

In cancer, communication is critical.

National non-profit begins a new chapter revealing new name, logo, and inclusive mission.

Alecensa (alectinib) was granted approval by the Food and Drug Administration (FDA) to treat patients with ALK-positive metastatic non–small cell lung cancer (NSCLC), according to Genentech (Roche), the manufacturer of the second-generation ALK inhibitor.

Zelboraf (vemurafenib) became the first approved drug to treat Erdheim-Chester disease (ECD).

Alfred L. Garfall lends insight as to what is new for myeloma treatment.

Lymphedema is not an uncommon secondary effect of cancer treatment. With no cure available, an effective long-term treatment effort is necessary for maximizing a cancer survivor's quality of life.

A cancer survivor describes all the wonderful people she has met on her arduous journey and what they mean to her.

Cancer survivor tries to actively practice gratitude during stressful holiday season and life's changes.

In an interview with CURE, Postow, a medical oncologist specializing in melanoma at Memorial Sloan Kettering Cancer Center, discussed the impressive efficacy seen with combining BRAF and MEK inhibitors for patients with melanoma.

A new drug, GSK2857916, was granted a breakthrough therapy designation by the FDA to treat patients who have relapsed or refractory multiple myeloma, according to GlaxoSmithKline (GSK), the manufacturer of the agent.

Recommendations made by patients living with MBC and health care providers who are cancer survivors will soon be disseminated throughout the health care system.

Akron, Ohio's best kept secret may revolutionize breast cancer treatment.